AZD-0328 – (220099-91-2)

AZD0328 is an experimental drug that acts as a selective α7 nicotinic receptor agonist. It has been shown to enhance cortical dopamine release and improve learning and attentional processes in rats.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

AZD0328 is an experimental drug that acts as a selective α7 nicotinic receptor agonist. It has been shown to enhance cortical dopamine release and improve learning and attentional processes in rats.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/AZD0328
https://pubchem.ncbi.nlm.nih.gov/compound/9794392
https://www.medchemexpress.com/azd0328.html
https://www.medkoo.com/products/9091
https://openinnovation.astrazeneca.com/clinical-research/clinical-molecules/azd0328.html
https://www.sciencedirect.com/science/article/abs/pii/S0006295209006364

Other Names	AZD0328, AZD 0328
IUPAC Name	(3R)-spiro[1-azabicyclo[2.2.2]octane-3, 2'-3H-furo[2, 3-b]pyridine]
CAS	220099-91-2
Molecular Weight	216.28
Molecular Formula	C13H16N2O
SMILES	C1CN2CCC1[C@@]3(C2)CC4=C(O3)N=CC=C4